Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils
Author(s) -
Ruth J. Pye,
Rodrigo Hamede,
Hannah V. Siddle,
Alison Caldwell,
Graeme W. Knowles,
Kate Swift,
Alexandre Kreiss,
Menna E. Jones,
A. Bruce Lyons,
GM Woods
Publication year - 2016
Publication title -
biology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.596
H-Index - 110
eISSN - 1744-957X
pISSN - 1744-9561
DOI - 10.1098/rsbl.2016.0553
Subject(s) - biology , immune system , immunology , population , antibody , wildlife disease , disease , pathology , ecology , medicine , wildlife , environmental health
Devil facial tumour disease (DFTD) is a recently emerged fatal transmissible cancer decimating the wild population of Tasmanian devils (Sarcophilus harrisii). Biting transmits the cancer cells and the tumour develops in the new host as an allograft. The literature reports that immune escape mechanisms employed by DFTD inevitably result in host death. Here we present the first evidence that DFTD regression can occur and that wild devils can mount an immune response against the disease. Of the 52 devils tested, six had serum antibodies against DFTD cells and, in one case, prominent T lymphocyte infiltration in its tumour. Notably, four of the six devils with serum antibody had histories of DFTD regression. The novel demonstration of an immune response against DFTD in wild Tasmanian devils suggests that a proportion of wild devils can produce a protective immune response against naturally acquired DFTD. This has implications for tumour-host coevolution and vaccine development.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom